An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption. The expert panel spent hours listening to presentations from Guardant, the FDA, and members...

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died. The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly...

You’d think if there were a vaccine that would prevent tens of thousands of cases of cancer a year, people would want it for themselves and for their kids. But new data being released Thursday ahead of the annual meeting of the American Society of Clinical Oncology show that just isn’t the case.Read the rest…

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Administration infighting over the national stockpile The health department’s preparedness office overseeing national stockpiles of emergency medical...

BATON ROUGE — Two abortion-inducing drugs could soon be reclassified as controlled and dangerous substances in Louisiana under a first-of-its-kind bill that received final legislative passage Thursday and is expected to be signed into law by the governor. Supporters of the reclassification of mifepristone and misoprostol, commonly known as “abortion...

How does a drug industry lobbying group move forward after years of upheaval, including having four CEOs in four years? This week on “The Readout LOUD,” STAT’s Chief Washington Correspondent Rachel Cohrs Zhang joins us to discuss the layoffs at trade group BIO and how things may be changing at the trade group. We also invite STAT reporter Eric Boodman...